Skip to main
SGHT

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. exhibits a positive financial outlook driven by anticipated stronger revenue growth, stemming from an expected increase in market share within the minimally invasive glaucoma surgery (MIGS) sector and more rapid adoption of its TearCare System. The company's Surgical Glaucoma segment is projected to sustain growth consistent with the overall MIGS market, positioning Sight Sciences for enhanced financial performance. Furthermore, analysts have maintained revenue projections of $75 million for 2025 and $82 million for 2026, while also showing improvement in earnings per share (EPS) estimates, indicating ongoing progress towards profitability.

Bears say

Sight Sciences Inc. faces a challenging financial outlook as it reiterated its 2025 revenue guidance of $72-76 million while anticipating mid-single-digit year-over-year declines in its Surgical Glaucoma segment for Q3 2025. The company confronts significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, delayed insurance coverage for its TearCare system, and persistent cash burn with no signs of improvement. Additionally, management has lowered its adjusted operating expense guidance for 2025, indicating struggles in managing costs despite efforts to achieve annualized savings through a reduction in workforce.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.02, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.02, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.